Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2005
08/09/2005US6927285 Genes for human telomerase reverse transcriptase and telomerase variants
08/09/2005US6927279 Prevention infections in cattle; vaccines; therapy for thrombosis
08/09/2005US6927235 Vaccine composition comprising iron phosphate as vaccine adjuvant
08/09/2005US6926910 Hydrophobe biomolecular structure
08/09/2005US6926898 Albumin fusion proteins
08/09/2005US6926897 comprising a fusion protein from at least one L1 protein of papillomaviruses and at least one E protein papillomaviruses, the fusion protein containing no papillomavirus-unspecfic epitopes
08/09/2005US6926896 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction
08/09/2005US6926893 Multi-stage cascade boosting vaccine
08/09/2005US6926888 producer cell ( encapsulated in a matrix which containing alginates) containing a plasmid that includes a nucleic acid sequence that encodes endostatin, angiostatin, thrombospondin, or prolactin
08/09/2005CA2155908C Method for improving utilisation of nutrients by ruminant or ruminant-like animals
08/09/2005CA2150346C Anti-feline herpes virus-1 recombinant antibody and gene fragment coding for said antibody
08/09/2005CA2135278C Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus
08/09/2005CA2109098C Activity-dependent neurotrophic factor
08/06/2005CA2553946A1 Antibodies against clostridium difficile toxins and uses thereof
08/04/2005WO2005071093A2 Chimpanzee adenovirus vaccine carriers
08/04/2005WO2005071088A2 Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
08/04/2005WO2005071084A1 Construction of gutted recombinant adenovirus effectively expressing antibodies comprising human constant region and uses thereof
08/04/2005WO2005071075A1 Peptide originating in epidermal growth factor receptor (egfr)
08/04/2005WO2005071069A1 Chimeric empty capsids of the infectious bursal disease virus (ibdv), obtainment process and applications
08/04/2005WO2005071068A1 EMPTY CAPSIDS (VLPs(-VP4)) OF THE INFECTIOUS BURSAL DISEASE VIRUS (IBDV), OBTAINMENT PROCESS AND APPLICATIONS
08/04/2005WO2005071067A2 Non-animal origin stabilizers and processes for producing the same
08/04/2005WO2005070967A2 Anti-cancer antibodies with reduced complement fixation
08/04/2005WO2005070959A2 Compositions comprising immune response altering agents and methods of use
08/04/2005WO2005070958A2 Lawsonia intracellularis subunit vaccines
08/04/2005WO2005070458A1 Improved iga production method
08/04/2005WO2005070457A1 Melphalan prodrugs
08/04/2005WO2005070456A2 Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
08/04/2005WO2005070455A1 Mucosal vaccine adjuvants containing bacterial flegellins as an active component
08/04/2005WO2005070454A2 A novel process of hepatitis a vaccine preparation
08/04/2005WO2005070453A1 Monoparamunity inducers based on attenuated rabbit myxoma viruses
08/04/2005WO2005070452A2 Methods for reducing somatic cell count in milky administration of mutated enterotoxins
08/04/2005WO2005070418A1 Immunomodulatory alkaloids
08/04/2005WO2005070415A1 Adjuvant compositions
08/04/2005WO2005070126A2 Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
08/04/2005WO2005070090A2 Regulatory t cells suppress autoimmunity
08/04/2005WO2005070041A2 Modulating vaccine against hiv nef protein-induced lymphocyte depletion
08/04/2005WO2005069855A2 Modulators of angiogenesis
08/04/2005WO2005069717A2 The use os anti-rh antibodies for treating acute thrombocytopenia associated with dengue hemorrhagic fever, hepatitis c and other microbial infections
08/04/2005WO2005060330A3 Freeze-dried vaccine adjuvant
08/04/2005WO2005058865A3 Assay for entactogens
08/04/2005WO2005054281A3 Protein nmb1125 and use thereof in pharmaceutical formulations
08/04/2005WO2005051990A3 Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
08/04/2005WO2005044859A3 Cd20 antibodies with increased fc receptor binding affinity and effector function
08/04/2005WO2005037206A3 Anti-cancer compounds and methods of use thereof
08/04/2005WO2005020891A3 Monoclonal antibodies against ricin toxin and methods of making and using thereof
08/04/2005WO2005002621A3 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
08/04/2005WO2005001059A3 Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions
08/04/2005WO2004108072A3 Delivery of immune response modifier compounds using metal-containing particulate support materials
08/04/2005WO2004098533A3 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
08/04/2005WO2004092360A3 The severe acute respiratory syndrome coronavirus
08/04/2005WO2004080385A3 Compositions and methods for diagnosing and treating an inflammation
08/04/2005WO2004053487A8 METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN βC
08/04/2005WO2004005316A3 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
08/04/2005WO2004004658A3 Methods and compositions relating to isoleucine boroproline compounds
08/04/2005WO2004003158A3 Methods and compositions for modulating and detecting wisp activity
08/04/2005US20050172352 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/04/2005US20050171339 Method of stabilizing protein
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171123 Quinazoline derivatives as medicaments
08/04/2005US20050171072 Therapeutic combinations and methods including IRM compounds
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171045 Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050170503 In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
08/04/2005US20050170500 Methods for identifying risk of melanoma and treatments thereof
08/04/2005US20050170443 Methods and use of binding components for improving assay specificity
08/04/2005US20050170436 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen
08/04/2005US20050170407 Reagents and methods useful for detecting diseases of the lung
08/04/2005US20050170398 Producing three or more non-identical antibodies in a single recombinant host cell in which a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed
08/04/2005US20050170366 Novel hair keratin-associated proteins
08/04/2005US20050170359 Treatment of vascular dysfunction and alzheimer's disease
08/04/2005US20050170355 Mixture of a nucleic acid and a chitosan with branching groups attached to the amino group, selected from alkyl groups with 2 or more carbon atoms, monosaccharides, oligosaccharides or polysaccharides; gene therapy, genetic vaccines, antisense therapy, anticarcinogenic agents, autoimmune diseases
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050169979 injectable liposomal composition for delivery of large amounts of water-soluble substance comprises a plurality of liposomal vesicles having a high weight ratio of lipid to encapsulated water-soluble substance which is distributed over the liposomal vesicles; high efficiency of encapsulation
08/04/2005US20050169943 Isolating outer membrane preparation, immunogenic component or extract from commensal Neisseria and formulating
08/04/2005US20050169942 Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics
08/04/2005US20050169940 Recombinant poxvirus not having a functional 3beta-hsd gene
08/04/2005US20050169939 Produced in cultured cells without Marek's disease contamination
08/04/2005US20050169938 Simple, nontoxic potentiation; without altering or interfering with immunogen epitope
08/04/2005US20050169937 Attacking immune tolerant species; having at least one consensus amino acid sequence
08/04/2005US20050169935 Compositions and methods for immunotherapy of cancer and infectious diseases
08/04/2005US20050169934 Computer assisted modeling of tumor antigen bound in major histocompatibility complex I groove; substituting at least first amino acid located in cytotoxic T lymphocyte epitope; reducing interference with T cell receptor binding; HER-2 related cancer
08/04/2005US20050169930 PSCA: prostate stem cell antigen and uses thereof
08/04/2005US20050169928 Antibodies which bind to proteins involved in cytoadhesion of plasmodlum falciparum ring-stage-infected erythrocytes
08/04/2005US20050169925 variable regions peptides for immunizing against amyloid plaque formation; biodrug for dementia, Alzheimer's disease, neuropathy, Down's syndrome, Creutzfeld Jacob disease, Parkinson's disease, amyotropic lateral sclerosis; neuroprotectants; hemostatic agent
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169921 administering an anti-C5 antibody for treating paroxysmal nocturnal hemoglobinuria blood disorder; reduction in lactate dehydrogenase; biodrug for hemoglobinuria, anemia, hemoglobinemia, dysphagia, fatigue, nitric oxide (NO) deficiency, erectile dysfunction, recurrent abdominal pain and thrombosis
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169918 selectively targeting; screening an effect of a Chemokine receptor (CCR4) modulating agent; adjusting the adhesion of T cells to endothelial cells; treating inflammatory skin disease; side effect reduction without affecting on other cells
08/04/2005US20050169917 Orphanin FQ receptor
08/04/2005US20050169914 Novel functions for decay accelerating factor (DAF) in inflammation
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169904 biodrug fusion protein comprising active mitochondrial protein or peptide, a mitochondrial membrane-permeant peptide and linking to a mitochondrial targeting sequence; targeting sequence is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm; mitochondrial disorders
08/04/2005US20050169901 controlling cytokine levels by administering extract or secreted products from microorganism; biosynthesis; atheroma, degenerative vascular disease or cardiovascular disease associated with inflammation of the coronary arteries; hypotensive agents, antilipemic agents, anticholesterol agents
08/04/2005US20050169900 inhibit proliferation of the malignant tumor by administering to the subject a plurality of a genetically manipulated cell which expresses cytokines, cellular adhesion molecules, immunostimulants, tumor associated antigens and tumor specific antigens; biodrugs as anticarcinogenic agents
08/04/2005US20050169898 Fusion of dendritic cells and antigen presenting cells; immunotherapy for stimulating an immune system; hybride cells; genetic engineering
08/04/2005US20050169892 Adeno-associated virus materials and methods
08/04/2005US20050169889 Immunogenic agent therapy using plasmapheresis or exchange transfusion
08/04/2005US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid
1 ... 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 ... 1823